Investigating effect of Helicobacter pylori treatment on improvement of nonalcoholic fatty liver parameters: a randomized trial by Kazemifar, Amir Mohammad et al.
ORIGINAL RESEARCH ARTICLE Open Access
Investigating effect of Helicobacter pylori
treatment on improvement of non-
alcoholic fatty liver parameters: a
randomized trial
Amir Mohammad Kazemifar1, Ali Akbar Shafikhani2, Elaheh HajiNoormohammadi3, Zahra Azarion3 and
Aliakbar Hajiaghamohammadi4*
Abstract
Background and objective: The correlation between the eradication of Helicobacter pylori (HP) and non-alcoholic
fatty liver disease (NAFLD) is a controversial one. The aim of this study is to investigate the effect of Helicobacter pylori
treatment on liver function tests and lipid profiles and to compare its effects with exercise therapy and diet alone.
Method: This was a double-blind randomized clinical trial conducted at Qazvin University of Medical Sciences. One
hundred patients with NAFLD having a positive test for urea breath testing were randomly assigned into one of the
intervention and comparison groups. The diet and physical activity program were given to two groups of patients for
8 weeks, three sessions per week. In addition to the above therapy, the patients in the intervention group also received
HP treatment for 2weeks. The data corresponding to anthropometric and clinical features before and after the
intervention were collected in both groups and compared using appropriate statistical methods.
Results: After the treatment interventions, the variables of weight, BMI, blood glucose, triglyceride, AST, ALT, total
cholesterol, and LDL-C were significantly decreased in both groups (p < .05). In the between-group comparisons, only
ALT was significantly lower in the intervention group (HP) (p < .05).
Conclusion: Findings of this study showed that the eradication of Helicobacter pylori could significantly improve the
ALT index, but it had no additional effect on changes in metabolic indicators.
Trial registration: Registration number: IRCT2015042020951N2
Name of trial registry: The study of treatment of Helicobacter pylori in improvement of non-alcoholic fatty liver disease
The date of registration: 2015-05-12
Where the full trial protocol can be accessed: https://fa.irct.ir/trial/18489
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Background
Non-alcoholic fatty liver disease (NAFLD) is a type of liver
injury caused by metabolic stress and hereditary sensitivity.
Generally, this disease is considered to be the liver mani-
festation of the metabolic syndrome [1, 2]. NAFLD includes
non-alcoholic fatty liver (NAFL), non-alcoholic steatohepa-
titis (NASH), and non-alcoholic steatohepatitis associated
with hepatic cirrhosis and hepatocellular carcinoma. The
incidence of NAFLD complications is rapidly increasing in
the world [2, 3]; therefore, the economic and clinical bur-
den of this disease is significant. Recently, except for the
known risk factors such as obesity, type 2 diabetes, hyper-
tension, and dyslipidemia, the role of the pathogenesis of
Helicobacter pylori (HP) is also discussed in the disease and
may be associated with NAFLD [4, 5].
HP is a Gram-negative bacterium that is selectively placed
in the gastric mucosa. This bacterium is the cause of most
cases of gastric ulcers and leads to development of some
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body weight could result in the sustained biochemical
improvement. Given the limitations expressed in the
diagnosis of the disease, for future studies, it is recom-
mended to use biopsy and magnetic resonance elasto-
graphy (MRE) to diagnose and MRE to follow up.
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